Search results for "Sclerosis"

showing 10 items of 1583 documents

Nonalcoholic fatty liver disease, association with cardiovascular disease and treatment. (I). Nonalcoholic fatty liver disease and its association wi…

2016

Non-alcoholic fatty liver disease (NAFLD) comprises a series of histologically lesions similar to those induced by alcohol consumption in people with very little or no liver damage. The importance of NAFLD is its high prevalence in the Western world and, from the point of view of the liver, in its gradual progression from steatosis to steatohepatitis, cirrhosis, and liver cancer. During the last decade it has been observed that NAFLD leads to an increased cardiovascular risk with acceleration of arteriosclerosis and events related to it, being the main cause of its morbidity and mortality. This review, updated to January 2016, consists of two parts, with the first part analysing the associa…

medicine.medical_specialtyCirrhosisDisease030204 cardiovascular system & hematologyGastroenterology03 medical and health sciences0302 clinical medicineNon-alcoholic Fatty Liver DiseaseRisk FactorsInternal medicineNonalcoholic fatty liver diseaseMedicineHumansGeneral Environmental Sciencebusiness.industryFatty liverGeneral Engineeringnutritional and metabolic diseasesArteriosclerosismedicine.diseaseAtherosclerosisdigestive system diseasesCardiovascular DiseasesDisease ProgressionGeneral Earth and Planetary Sciences030211 gastroenterology & hepatologySteatohepatitisSteatosisbusinessLiver cancerClinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis
researchProduct

Nonalcoholic fatty liver disease, association with cardiovascular disease and treatment (II). The treatment of nonalcoholic fatty liver disease.

2016

Disease nonalcoholic fatty liver disease (NAFLD) comprises a series of histologically similar to those induced by alcohol consumption in people with very little or no liver damage same. The importance of NAFLD is its high prevalence in our Western societies, from the point of view liver in its progressive evolution from steatosis to steatohepatitis, cirrhosis and liver cancer. During the last decade it has been observed that NAFLD leads to an increased cardiovascular risk with accelerated atherosclerosis and cardiovascular events, the leading cause of morbidity and mortality. This updated January 2016 revision consists of two parts. In this second part, the treatment of NAFLD and its influe…

medicine.medical_specialtyCirrhosisDiseaseGastroenterologyLiver diseaseNon-alcoholic Fatty Liver DiseaseRisk FactorsInternal medicineNonalcoholic fatty liver diseasemedicineAnimalsHumansGeneral Environmental Sciencebusiness.industryGeneral EngineeringArteriosclerosismedicine.diseaseAtherosclerosisdigestive system diseasesCardiovascular DiseasesDisease ProgressionGeneral Earth and Planetary SciencesSteatosisSteatohepatitisLiver cancerbusinessClinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis
researchProduct

Atherosclerosis, degenerative aortic stenosis and statins

2009

Aortic stenosis is the most common valvular heart disease among adult subjects in western countries The current treatment for aortic stenosis is aortic valve replacement. The possibility of a medical treatment that can slow the progression of aortic stenosis is very fascinating and statins have been tested to reduce the progression of degenerative aortic stenosis (DAS). The rationale for statin treatment in DAS has a deep pathophysiological substrate, in fact inflammation and lipid infiltration constitute the same histopathological pattern of both aortic stenosis and atherosclerosis and these two conditions have the same risk factors. Whether retrospective studies have shown some efficacy o…

medicine.medical_specialtyClinical BiochemistryInflammationlaw.inventionCoronary artery diseaseRandomized controlled trialAortic valve replacementlawInternal medicineDrug DiscoverymedicineAnimalsHumansPharmacologyEvidence-Based Medicinebusiness.industryvalvular heart diseaseRetrospective cohort studyAortic Valve Stenosismedicine.diseaseAtherosclerosisSettore MED/11 - Malattie Dell'Apparato Cardiovascolareatherosclerosis aortic stenosis statinStenosiscardiovascular systemCardiologyMolecular Medicinemedicine.symptomHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessCalcification
researchProduct

Use of Expert Consensus to Improve Atherogenic Dyslipidemia Management

2013

Abstract Introduction and objectives Although atherogenic dyslipidemia is a recognized cardiovascular risk factor, it is often underassessed and thus undertreated and poorly controlled in clinical practice. The objective of this study was to reach a multidisciplinary consensus for the establishment of a set of clinical recommendations on atherogenic dyslipidemia to optimize its prevention, early detection, diagnostic evaluation, therapeutic approach, and follow-up. Methods After a review of the scientific evidence, a scientific committee formulated 87 recommendations related to atherogenic dyslipidemia, which were grouped into 5 subject areas: general concepts (10 items), impact and epidemi…

medicine.medical_specialtyConsensusDelphi TechniqueGuidelines as TopicScientific evidenceTherapeutic approachRisk FactorsMultidisciplinary approachEpidemiologymedicineHumansRisk factorDyslipidemiascomputer.programming_languageAtherogenic dyslipidemiaEvidence-Based Medicinebusiness.industryExpert consensusGeneral MedicineAtherosclerosisAtherogenic dyslipidemia Cardiovascular risk Consenso Consensus Delphi Dislipemia aterogénica HDL-C LDL-C Riesgo cardiovascular high-density lipoprotein cholesterol low-density lipoprotein cholesterolCardiovascular DiseasesFamily medicinePhysical therapybusinesscomputerDelphiRevista Española de Cardiología (English Edition)
researchProduct

ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis.

2018

Background and purpose: Multiple sclerosis (MS) is a complex disease of the central nervous system. As new drugs are becoming available, knowledge on diagnosis and treatment must continuously evolve. There is therefore a need for a reference tool compiling current data on benefit and safety, to aid professionals in treatment decisions and use of resources across Europe. The European Committee of Treatment and Research in Multiple Sclerosis (ECTRIMS) and the European Academy of Neurology (EAN) have joined forces to meet this need. The objective was to develop an evidence-based clinical practice guideline for the pharmacological treatment of people with MS to guide healthcare professionals in…

medicine.medical_specialtyConsensusMultiple SclerosisdemyelinatingComplex diseasedisease-modifying therapies GRADE methodology guideline Multiple sclerosis Neurology Neurology (clinical)Outcome (game theory)Pharmacological treatmentImmunomodulation03 medical and health sciences0302 clinical medicineIntervention (counseling)GRADE methodologyAgency (sociology)Nominal group techniquemedicineImmunologic FactorsRelevance (law)Humans030212 general & internal medicineneurological disorderdisease-modifying therapiesIntensive care medicineSocieties MedicaldiseaseEvidence-Based Medicinebusiness.industryMultiple sclerosisdisease-modifying treatmentGuidelinemedicine.diseaseresearch methodEuropeNeurologymultiple sclerosiFamily medicinePractice Guidelines as TopicNeurology (clinical)businessguideline030217 neurology & neurosurgeryEuropean journal of neurology
researchProduct

Informing MS patients on treatment options: a consensus on the process of consent taking

2020

Abstract\ud In the last years, change in multiple sclerosis (MS) therapeutic scenario has highlighted the need for an improved doctor-patient communication in advance of treatment initiation in order to allow patient’s empowerment in the decision-making process.\ud Aims\ud The aims of our project were to review the strategies used by Italian MS specialists to inform patients about treatment options and to design a multicentre shared document that homogenizes the information about disease-modifying treatment (DMTs) and the procedure of taking informed consent in clinical practice.\ud Results\ud The new resource, obtained by consensus among 31 neurologists from 27 MS Centres in Italy with the…

medicine.medical_specialtyConsensusProcess (engineering)media_common.quotation_subjectDermatologyDisease modifying treatment; Informed consent; Multiple sclerosisMultiple sclerosis03 medical and health sciences0302 clinical medicineResource (project management)Informed consentDisease modifying treatmentmedicineHumans030212 general & internal medicineInformed consentEmpowermentmedia_commonPhysician-Patient Relationsbusiness.industryTreatment optionsGeneral MedicineClinical PracticePsychiatry and Mental healthItalyFamily medicineDisease modifying treatment; Informed consent; Multiple sclerosis; Consensus; Humans; Italy; Physician-Patient Relations; Informed Consent; Multiple SclerosisSettore MED/26 - NeurologiaNeurology (clinical)Decision processbusiness030217 neurology & neurosurgery
researchProduct

Variants translating reduced expression of the beta estrogen receptor gene were associated with increased carotid intima media thickness : a cross-se…

2021

Abstract Background There is debate on the role of estrogens in modulating the risk for atherosclerosis in women. Our purpose was to investigate whether the size of the estrogenic impact was independently associated with variation of carotid intima-media thickness (IMT) in healthy late postmenopausal women. The levels of circulating estrogens have been used in previous studies but the influence of SNPs of the estrogen receptors (ER) α and β has not been investigated.Methods We performed a crossed-sectional study of 91 women in a university hospital. We used a double approach in which, in addition to the measurement of estradiol levels by ultrasensitive methods, genetic variants (SNPs) assoc…

medicine.medical_specialtyCross-sectional studyArterioesclerosis - Factores de riesgo.Estrogen receptorEstrógenos.Single-nucleotide polymorphismArteriosclerosis - Risk factors.Menopausia.03 medical and health sciences0302 clinical medicineInternal medicineGenotypemedicineVitamin D and neurologySNPcardiovascular diseases030212 general & internal medicinebusiness.industryMenopause.General MedicineEstrogen.Carotid artery.EndocrinologyIntima-media thickness030220 oncology & carcinogenesisArteria carótida.cardiovascular systembusinessEstrogen receptor alpha
researchProduct

Size and subclasses of low-density lipoproteins in patients with obstructive sleep apnea.

2012

Patients with obstructive sleep apnea (OSA) have proatherogenic dyslipidemia. We analyzed predictors of low-density lipoproteins' (LDLs) size in patients with OSA. In a cross-sectional study including 58 participants with OSA (30 without the metabolic syndrome [MetS] and 28 with MetS), we evaluated the size of LDL by gradient gel electrophoresis. Compared with patients without the MetS, those with MetS showed lower LDL size ( P = .007), due to a reduction in large LDL-I particles ( P = .002) and an increase in small, dense LDL-IIIA ( P = .048) and LDL-IIIB ( P = .037). The size of LDL correlated inversely with age ( r = −.268, P = .042) and serum triglycerides ( r = −.364, P = .005), and p…

medicine.medical_specialtyCross-sectional studyPolysomnography10265 Clinic for Endocrinology and Diabetology610 Medicine & healthPolysomnography2705 Cardiology and Cardiovascular MedicineInternal medicinemedicineLow densityobstructive sleep apnea metabolic syndrome low-density lipoprotein size small dense low-density lipoprotein atherosclerosisHumansIn patientDyslipidemiasMetabolic SyndromeSleep Apnea Obstructivemedicine.diagnostic_testbusiness.industrySleep apneamedicine.diseaseLipoproteins LDLObstructive sleep apneaCross-Sectional StudiesEndocrinologyLinear Modelslipids (amino acids peptides and proteins)Metabolic syndromeCardiology and Cardiovascular MedicinebusinessDyslipidemia
researchProduct

Therapeutic dosages of oral or transdermal estradiol did not modify sCD40L levels in postmenopausal women.

2008

The CD40/CD40L system is considered a crucial modulator of the inflammatory process underlying the progression and complication of atheroma plaques. The soluble fraction of CD40L (sCD40L) is a reliable indicator of the CD40/CD40L system. Our purpose was to investigate whether a therapeutic dose of estradiol, by either the oral or the transdermal route, was associated with changes in circulating levels of sCD40L. Forty-seven women completed a 4-week course of treatment with either oral estradiol valerate (2 mg/day, 20 women) or transdermal estradiol (50 microg/day, 27 women). Serum levels of sCD40L were measured by conventional enzyme-linked immunosorbent assay. Oral, but not transdermal est…

medicine.medical_specialtyDoseEndocrinology Diabetes and MetabolismCD40 LigandAdministration OralEnzyme-Linked Immunosorbent AssayPharmacologyAdministration CutaneousFollicle-stimulating hormoneEndocrinologyTherapeutic indexInternal medicinemedicineHumansCD40 AntigensTriglyceridesTransdermalmedicine.diagnostic_testEstradiolbusiness.industryTransdermal routeEstradiol valerateObstetrics and Gynecologymedicine.diseaseAtherosclerosisMenopausePostmenopauseEndocrinologyCholesterolFemaleFollicle Stimulating HormoneLipid profilebusinessmedicine.drugGynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
researchProduct

Predictors of self-reported heart failure - results from the Gutenberg Health study

2013

medicine.medical_specialtyEjection fractionbusiness.industryCoronary arteriosclerosismedicine.diseaseNew York Heart Association ClassificationInternal medicineHeart failureArea under curvemedicineCardiologyMedical historyCardiology and Cardiovascular MedicineSelf reportbusinessCohort studyClinical psychologyEuropean Heart Journal
researchProduct